Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.

Strober, Bruce; Gottlieb, Alice B; Sherif, Bintu; Mollon, Patrick; Gilloteau, Isabelle; McLeod, Lori; Fox, Todd; Mordin, Margaret; Gnanasakthy, Ari; Papavassilis, Charis; Lebwohl, Mark G

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.

Strober, Bruce; Gottlieb, Alice B; Sherif, Bintu; Mollon, Patrick; Gilloteau, Isabelle; McLeod, Lori; Fox, Todd; Mordin, Margaret; Gnanasakthy, Ari; Papavassilis, Charis; Lebwohl, Mark G.

Afiliação

Strober B; University of Connecticut, Farmington, Connecticut; Probity Medical Research, Waterloo, Ontario, Canada.
Gottlieb AB; New York Medical College, Valhalla, New York.
Sherif B; RTI Health Solutions, Research Triangle Park, North Carolina.
Mollon P; Novartis Pharma AG, Basel, Switzerland.
Gilloteau I; Novartis Pharma AG, Basel, Switzerland. Electronic address: isabelle.gilloteau@novartis.com.
McLeod L; RTI Health Solutions, Research Triangle Park, North Carolina.
Fox T; Novartis Pharma AG, Basel, Switzerland.
Mordin M; RTI Health Solutions, Ann Arbor, Michigan.
Gnanasakthy A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
Lebwohl MG; Mt Sinai Medical Center, New York, New York.

J Am Acad Dermatol ; 76(4): 655-661, 2017 Apr.

Article em En | MEDLINE | ID: mdl-28087133

Assuntos

Anticorpos Monoclonais/uso terapêutico; Fármacos Dermatológicos/uso terapêutico; Etanercepte/uso terapêutico; Imunossupressores/uso terapêutico; Psoríase/tratamento farmacológico; Adulto; Anticorpos Monoclonais Humanizados; Método Duplo-Cego; Feminino; Humanos; Injeções Subcutâneas; Interleucina-17/antagonistas & inibidores; Masculino; Pessoa de Meia-Idade; Satisfação do Paciente; Psoríase/psicologia; Qualidade de Vida; Recidiva; Inquéritos e Questionários; Resultado do Tratamento; Fator de Necrose Tumoral alfa/antagonistas & inibidores

Palavras-chave

Dermatology Life Quality Index; patient-reported outcome; psoriasis; secukinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos / Etanercepte / Imunossupressores / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google